文献速递心律失常

阿哌沙班与肝素/维生素K拮抗剂在房颤电复律患者中的比较:EMANATE试验

Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.
PubMed 文献 · Eur Heart J · 2018-01-01

结果显示阿哌沙班组卒中0/753 vs 肝素/VKA组6/747(RR 0,95%CI 0-0.64,名义P=0.015),大出血和临床相关非大出血两组均低且无显著差异。

要点

  • 阿哌沙班组卒中0例,肝素/VKA组6例,RR 0(95%CI 0-0.64,名义P=0.015)。
  • 大出血3/735 vs 6/721(RR 0.49,95%CI 0.10-2.07,名义P=0.338),无显著差异。
  • 临床相关非大出血11 vs 13(RR 0.83,95%CI 0.34-1.89,名义P=0.685)。

核心结论

  • 阿哌沙班与肝素/VKA在房颤复律患者中卒中、系统性栓塞、死亡和出血发生率均低。

研究设计与样本

  • 阿哌沙班5 mg每日两次,符合年龄≥80岁、体重≤60 kg或血肌酐≥133 µmol/L中两项者减至2.5 mg每日两次。
  • 允许研究者酌情进行影像学检查和/或负荷剂量10 mg(下调至5 mg)以加速复律。

主要发现

  • 卒中:阿哌沙班组0/753 vs 肝素/VKA组6/747,RR 0(95%CI 0-0.64),名义P=0.015。
  • 系统性栓塞:两组均无事件。
  • 死亡:2 vs 1,RR 1.98(95%CI 0.19-54.00),名义P>0.999。
  • 大出血:3/735 vs 6/721,RR 0.49(95%CI 0.10-2.07),名义P=0.338。
  • 临床相关非大出血:11 vs 13,RR 0.83(95%CI 0.34-1.89),名义P=0.685。

临床怎么用

  • 对于房颤复律患者,阿哌沙班可作为肝素/VKA的替代抗凝选择,卒中和大出血风险低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The primary objective was to compare apixaban to heparin/vitamin K antagonist (VKA) in patients with atrial fibrillation (AF) and ≤48 h anticoagulation prior to randomization undergoing cardioversion. METHODS: One thousand five hundred patients were randomized. The apixaban dose of 5 mg b.i.d. was reduced to 2.5 mg b.i.d. in patients with two of the following: age ≥ 80 years, weight ≤ 60 kg, or serum creatinine ≥ 133 µmol/L. To expedite cardioversion, at the discretion of the investigator, imaging and/or a loading dose of 10 mg (down-titrated to 5 mg) was allowed. The endpoints for efficacy were stroke, systemic embolism (SE), and death. The endpoints for safety were major bleeding and clinically relevant non-major (CRNM) bleeding. RESULTS: There were 1038 active and 300 spontaneous cardioversions; 162 patients were not cardioverted. Imaging was performed in 855 patients, and 342 received a loading dose of apixaban. Comparing apixaban to heparin/VKA in the full analysis set, there were 0/753 vs. 6/747 strokes [relative risk (RR) 0; 95% confidence interval (95% CI) 0-0.64; nominal P = 0.015], no SE, and 2 vs. 1 deaths (RR 1.98; 95% CI 0.19-54.00; nominal P > 0.999). In the safety population, there were 3/735 vs. 6/721 major (RR 0.49; 95% CI 0.10-2.07; nominal P = 0.338) and 11 vs. 13 CRNM bleeding events (RR 0.83; 95% CI 0.34-1.89; nominal P = 0.685). On imaging, 60/61 with thrombi continued randomized treatment; all (61) were without outcome events. CONCLUSIONS: Rates of strokes, systemic emboli, deaths, and bleeds were low for both apixaban and heparin/VKA treated AF patients undergoing cardioversion. CLINICAL TRIALS.GOV NUMBER: NCT02100228.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Ezekowitz MD, Pollack CV, Halperin JL, et al. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018. PMID: 29659797. doi:10.1093/eurheartj/ehy148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。